Table 3. Incidence of treatment-related adverse events.
No. adverse events | Grade 1–2 | Grade 3* |
---|---|---|
Non-hematologic | ||
Fatigue | 5 | 0 |
Nausea | 3 | 0 |
Proteinuria | 3 | 0 |
Hematuria | 2 | 0 |
Vomiting | 1 | 0 |
Diarrhea | 1 | 0 |
Infusion reaction | 1 | 0 |
Pruritus | 1 | 0 |
Myalgia | 1 | 0 |
Cystitis | 1 | 0 |
Cough | 1 | 0 |
Hypertension | 1 | 0 |
Alk Phos elevation | 1 | 0 |
AST elevation | 1 | 0 |
Cardiac chest pain | 0 | 1 |
Hematologic | ||
Anemia | 3 | 0 |
Leukopenia | 2 | 0 |
Neutropenia | 2 | 0 |
Lymphopenia | 1 | 0 |
Thrombocytopenia | 1 | 0 |
*, no grade 4 or 5 toxicities were observed. Alk Phos, alkaline phosphatase; AST, aspartate aminotransferase.